Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101
November 17, 2015 7:00 AM ESTThree-Party Collaboration Will Explore Synergies Between AstraZenecas Leading PARP Inhibitor and Ceruleans Topoisomerase Inhibitor
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (Nasdaq: CERU) announced today that it has entered into a collaboration with AstraZeneca AB (AstraZeneca) and the National Cancer Institute (NCI), part of the National Institutes of Health, to... More
Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results
November 16, 2015 4:35 PM ESTConference Call Today at 4:30 p.m.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended September 30, 2015.
During the third quarter, we strengthened our management team by appointing... More
